HLB (028300) gave back the previous trading day's gains after just one day, starting weakly again. In early trading on the 26th, the stock was trading in the 37,000-won range.

As of 9:36 a.m. on the 26th, HLB was trading at 37,650 won, down 650 won (1.70%) from the previous trading day. Trading volume at the same time stood at 194,313 shares.

■ Repeated 'Limited Rebounds' Within a Downward Trend

HLB's stock has shown a pattern of intermittent rebounds amid an overall decline in its share price recently. Starting at 42,850 won on the 18th, the stock fell each trading day—to 42,350 won on the 19th, 40,100 won on the 20th, 38,600 won on the 21st, and 37,800 won on the 24th.

However, on the 25th, the stock managed a rare rebound, closing at 38,450 won, up 600 won (1.59%) from the previous trading day. Yet in early trading on the 26th, it fell again by more than 1%, giving back much of the previous day's gains.

In particular, the market interprets the recent trend not as a simple alternation of rises and falls, but rather as limited rebounds embedded within an overall declining price trend.

Accordingly, the supply and demand flow in the 37,000-won range and changes in intraday declines on this day are expected to be key observation points for the short-term share price.

■ Progress on Liver Cancer Drug Approval Still a Key Variable

Developments related to HLB's liver cancer drug remain one of the key variables for its share price. HLB has been pursuing U.S. approval of its combination therapy of rivoceranib and camrelizumab as a first-line treatment for liver cancer. Procedures involving the U.S. Food and Drug Administration (FDA) and subsequent responses remain matters the market must continue to monitor.

For new drug development companies, stock price volatility can expand significantly depending on clinical trial results, approval procedures, and consultations with regulatory authorities. Even if a short-term rebound occurs, it is necessary to separately confirm whether the trend will continue.

[Stocks can experience greatly expanded price volatility depending on domestic and international market trends, industry supply and demand, corporate earnings and disclosures, commodity prices, and policy changes. There is a possibility of sharp short-term surges or drops due to changes in investor sentiment, so future direction should not be determined solely by intraday fluctuations. Please comprehensively check official disclosures, earnings, business progress, and market supply and demand. This article is not intended to recommend the purchase or sale of any specific stock or to guarantee investment returns. This article was written with AI assistance.]